HLH and TET2 Mutation Presenting after First Cycle of CLL Treatment.

Allison J Geiger, Demet Gokalp Yasar, Kajal V Sitwala

Open access · diamondAbstract read

In one paragraph

Article in Clinical medicine & research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.6field-weighted citation impact, top 25% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

A Distinctive Case of Hemophagocytic Lymphohistiocytosis in Chronic Lymphocytic Leukemia.Journal of investigative medicine high impact case reports
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Allison J GeigerWarde Medical Laboratory, Ann Arbor, Michigan.

Demet Gokalp YasarDepartment of Hematology/Oncology, Marshfield Clinic Health System, Marshfield, Wisconsin.

Kajal V SitwalaDepartment of Laboratory Medicine, Marshfield Clinic Health System, Marshfield, Wisconsin kajal.sitwala@gmail.com.

Marshfield Clinic · USWarde Medical Laboratory · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here we report development of hemophagocytic lymphohistiocytosis (HLH), along with unmasking of a TET2-mutated myeloid neoplasm, after initial doses of bendamustine and rituximab for longstanding chronic lymphocytic leukemia (CLL). After many years of CLL showing minimally progressive lymphocytosis, the patient's white blood cell count began to decline in parallel with neutrophil count, hemoglobin, and platelet count. Bone marrow biopsy showed partial CLL involvement; bendamustine+rituximab therapy was augmented with granulocyte colony-stimulating factor (g-CSF) and romiplostim to mitigate worsening pancytopenia, without response. Laboratory evaluation revealed a pattern supportive of the clinical impression of HLH, while bone marrow biopsy showed persistent CLL, new reticulin fibrosis, megakaryocytic proliferation, and 32% mutated TET2, but no compelling morphologic evidence of hemophagocytosis. The patient recovered with dexamethasone and g-CSF support.

Indexed as

DioxygenasesLeukemia, Lymphocytic, Chronic, B-CellLymphohistiocytosis, HemophagocyticBendamustine HydrochlorideDNA-Binding ProteinsGranulocyte Colony-Stimulating FactorHumansRituximabBendamustine HydrochlorideDioxygenasesDNA-Binding ProteinsGranulocyte Colony-Stimulating FactorRituximabTET2 protein, humanChronic B-cellHemophagocyticLymphocytic leukemiaLymphohistiocytosisTET2 protein

Identifiers

PMID37985171

DOI10.3121/cmr.2023.1804

PMCPMC10659132

OpenAlexW4388836298

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.